Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-01-31
2006-01-31
Barts, Samuel (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S050000, C514S043000, C514S042000, C536S028500
Reexamination Certificate
active
06992072
ABSTRACT:
The invention relates to the use of active ingredients, which increase the concentration of pyrimidine-based elements for nucleic acid biosynthesis in the body, in particular to the use of pyrimidine nucleosides and/or prodrugs produced therefrom, for reducing the side-effects of inhibitors of nucleic acid biosynthesis or their precursors, in particular by activating the biosynthesis of mitochondrial DNA (mtDNA). The invention also relates to the use of said active ingredients, in particular pyrimidine nucleosides and/or prodrugs for producing pharmaceutical preparations for reducing the aforementioned side-effects and to combinations or products for administering active ingredients of this type, in particular pyrimidine nucleosides and/or prodrugs produced therefrom, comprising inhibitors of nucleic acid biosynthesis or their precursors. The invention further relates to methods for treating the side-effects of inhibitors of nucleic acid biosynthesis or their precursors using the aforementioned active ingredients, in particular pyrimidine nucleosides and/or prodrugs produced therefrom, or the aforementioned combinations or products and to corresponding pharmaceutical preparations. Side-effects of HAART (Highly Active Anti-Retroviral Therapy) and side-effects of other anti-viral nucleoside analogous agents, which inhibit the mitochondrial γ-polymerases, can in particular be prophylactically and/or therapeutically treated in this manner.
REFERENCES:
patent: 5141943 (1992-08-01), Naguib et al.
patent: 5567689 (1996-10-01), Sommadossi et al.
patent: 114 411 (1975-08-01), None
patent: 93 01202 (1993-01-01), None
patent: WO 93-01202 (1993-01-01), None
patent: 93 12128 (1993-06-01), None
patent: 00 11952 (2000-03-01), None
patent: 00 50043 (2000-08-01), None
Martinez et al., Clinical infectious disease: an official publication of the Infectious Disease Society of America, (Nov. 2000) 31 (5) 1266-73. Electronic Publication: Nov. 6, 2000)(Abstract Sent).
U.A. Walker, et al., “Evidence of Nucleoside Analogue Reverse Transcriptase Inhibitor-Associated Genetic and Structural Defects of Mitochondria in Adipose Tissue of HIV-Infected Patients”, JAIDS, Journal of Acquired Immune Deficiency Syndromes, vol. 29, No. 2, Feb. 1, 2002, pp. 117-121.
J. Amin, et al., “Combined Analysis of Two-Year Follow-Up From Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: Ozcombo 1 and 2”, HIV Clin Trials, 4(4), 2003, pp. 252-261.
G.Chene, et al., “Role of Long-Term Nucleoside-Analogue Therapy in Lipodystrophy and Metabolic Disorders in Human Immunodeficiency Virus-Infected Patients”, CID, 34, Mar. 1, 2002, pp. 649-657.
V. Joly, et al., “Increased Risk of Lipoatrophy Under Stavudine in HIV-1 Infected Patients: Results of a Substudy from a Comparative Trial”, AIDS, vol. 16, No. 18, 2002, pp. 2447-2454.
A. Martin, et al., “Reversibility of Lipoatrophy in HIV-Infected Patients 2 Years After Switching From a Thymidine Analogue to Abacavir: The Mitox Extension Study”, AIDS, vol. 18, No. 7, 2004, pp. 1029-1036.
G.A. McComsey, et al., “Improvements in Lipoatrophy, Mitochondrial DNA Levels and Fat Apoptosis After Replacing Stavudine with Abacavir or Zidovudine”, AIDS, vol. 19, No. 1, 2005, pp. 15-23.
C.L. Cherry, et al., “Increased Adipocyte Apoptosis in Lipoatrophy Improves within 48 Weeks of Switching Patient Therapy from Stavudine to Abacavir or Zidovudine”, J Acquir Immune Defic Syndr, vol. 38, No. 3, Mar. 1, 2005, pp. 263-267.
U.A. Walker, et al., “Uridine Abrogates the Adverse Effects of Pyrimidine Analogues on Adipose Cell Functions”, Antiviral Therapy, 9, 2004, w/attached manuscript pp. 1-26.
C.J. Van Groeningen, et al., “Clinical and Pharmacokinetic Studies of Prolonged Administration of High-Dose Uridine Intended for Rescue from 5-Fu Toxicity”, Cancer Treatment Reports, vol. 70, No. 6, Jun. 1986, pp. 745-750.
A. Leyva, et al., “Phase I and Pharmacokinetic Studies of High-Dose Uridine Intended for Rescue from 5-Fluorouracil Toxicity”, Cancer Research, vol. 44, Dec. 1984, pp. 5928-5933.
C.J. Van Groeningen, et al., “Reversal of 5-Fluorouracil-Induced Toxicity by Oral Administration of Uridine”, Annals of Oncology, vol. 4, 1993, pp. 317-320.
C.J. Van Groeningen, et al., “Phase I Clinical and Pharmacokinetics Study of Orally Administered Uridine”, Proceedings of the AACR, vol. 28, Mar. 1987, p. 195.
D.P. Kelsen, et al., “Phase I Trial of PN401, an Oral Prodrug of Uridine to Prevent Toxicity from Fluorouracil in Patients with Advanced Cancer”, Journal of Clinical Oncology, vol. 15, No. 4, Apr. 1997, pp. 1511-1517.
M. Hidalgo, et al., “Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients with Advanced Solid Malignancies”, Journal of Clinical Oncology, vol. 18, No. 1, Jan. 2000, pp. 167-177.
T.N. Kakuda, et al., “Pharmacology of Nucleoside and Nucleotide Reverse Transcriptase Inhibitor-Induced Mitochondrial Toxicity”, Clinical Therapeurtics, vol. 22, No. 6, pp. 685-708, Jun. 2000.
O.M. Ashour, et al., “Modulation of 5-Fluorouracil Host Toxicity by 5-(Benzyloxybenzyl)Barbituric Acid Acyclonucleoside, A Uridine Phosphorylase Inhibitor, and 2′,3′,5′-Tri-0-Acetaluridine, a Prodrug of Uridine”, Biochemical Pharmacology, vol. 60, No. 3, pp. 427-431, 2000.
Barts Samuel
Henry Michael C.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Pharma Nord ApS
LandOfFree
Combating side-effects does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combating side-effects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combating side-effects will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3524648